Second, data on genomic alterations were missing for most patients, while these alterations are of increasing importance for targeted therapy (i.e., isocitrate dehydrogenase and fibroblast growth factor receptor alterations) and prognosis.23–29 In a phase II study, 108 patients with previously treated advanced CCA with FGFR2 fusions or rearrangements received infigratinib. Here, IDH3A is linked to cholangiocarcinoma.